n/a
Abstract Title:

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia.

Abstract Source:

Mini Rev Med Chem. 2020 ;20(6):483-497. PMID: 31660811

Abstract Author(s):

Xu Hu, Yan Wang, Xiang Gao, Shengtao Xu, Linghe Zang, Yan Xiao, Zhanlin Li, Huiming Hua, Jinyi Xu, Dahong Li

Article Affiliation:

Xu Hu

Abstract:

First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.

Study Type : Review

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.